MedTrace Logo

Nurse-led Medicines' Monitoring in Care Homes: a Process Evaluation

NCT03110471 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-06-24

Study results available
· View outcomes & findings →

Summary

Lay Summary:

The investigators have shown in randomised controlled trials and observation studies that structured nurse-led medicines' monitoring using the WWADR Profile benefits patients, for example, by reducing pain and sedation and identifying high risk cardiovascular conditions. The investigators now aim to understand what is needed to sustain implementation of the WWADR Profile in routine practice and explore future directions.

The participants of the investigators previous research, 5 newly recruited care homes, and stakeholders - care home managers, carers, healthcare professionals, and service users - will be asked to contribute interviews, observations and reflective diaries/ accounts. The investigators are interested in their experiences of medication use, medication management, adverse effects and barriers and facilitators of medicine monitoring, and how electronic devices can enhance nurse-led monitoring.

Conditions

Interventions

BEHAVIORAL

West Wales Adverse Drug Reaction (WWADR) Profile

Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement

BEHAVIORAL

usual care

usual care

Sponsors & Collaborators

  • Abertawe Bro Morgannwg University Health Board

    collaborator OTHER

  • Swansea University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-03-30
Completion
2018-03-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03110471 on ClinicalTrials.gov